Clinical Stage IV Gastric Cancer AJCC v8
Oncology·MeSH: Uterine Neoplasms
Prevalence
10.0 / 100K
Incidence
6.1 / 100K/yr
1 drug in development·1 company·4 clinical trials
Drug Pipeline by Phase
Phase 1(1)
| Drug | Company |
|---|---|
| Mitomycin | IGM Biosciences, Inc. (IGMS) |
Frequently asked questions
How many drugs are in development for Clinical Stage IV Gastric Cancer AJCC v8?
BioSniper tracks 1 drug in development for Clinical Stage IV Gastric Cancer AJCC v8 across 1 company.
How many clinical trials target Clinical Stage IV Gastric Cancer AJCC v8?
There are 4 clinical trials targeting Clinical Stage IV Gastric Cancer AJCC v8 tracked by BioSniper.
What is the prevalence of Clinical Stage IV Gastric Cancer AJCC v8?
The estimated prevalence of Clinical Stage IV Gastric Cancer AJCC v8 is approximately 10.0 per 100,000 population.
Deep-dive into Clinical Stage IV Gastric Cancer AJCC v8
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis